Erratum: Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy(J Clin Invest. (2017)127:6(2118–2132) DOI: 10.1172/JCI92001);Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy

Journal of Clinical Investigation

Volumn 127, Issue 6, 2017, Pages 2118-2132

  Walker, Lauren Elizabeth ^a   Frigerio, Federica ^b   Ravizza, Teresa ^b   Ricci, Emanuele ^a   Tse, Karen ^a   Jenkins, Rosalind E ^a   Sills, Graeme John ^a   Jorgensen, Andrea ^a   Porcu, Luca ^b   Thippeswamy, Thimmasettappa ^c   Alapirtti, Tiina ^d   Peltola, Jukka ^d   Brodie, Martin J ^e   Park, Brian Kevin ^a   Marson, Anthony Guy ^a   Antoine, Daniel James ^a   Vezzani, Annamaria ^b   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c IOWA STATE UNIVERSITY   (United States)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; ANTIINFLAMMATORY AGENT; BOX A; DISULFIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; IFENPRODIL; INTERLEUKIN 1 RECEPTOR TYPE I; PROTEIN INHIBITOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN; ISOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAM; ENDOTHELIUM CELL; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SEIZURE; SENSIBILITY; ADOLESCENT; AGED; ANIMAL; BLOOD; BRAIN; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PRECLINICAL STUDY; RECEIVER OPERATING CHARACTERISTIC; SPRAGUE DAWLEY RAT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; BIOMARKERS; BRAIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; EPILEPSY; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RATS, SPRAGUE-DAWLEY; ROC CURVE; YOUNG ADULT;

EID: 85020163456     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI129285     Document Type: Erratum

References (61)

1. Pitkänen A, Engel J. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231-241.
2. Kwan P, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077.
3. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31-40.
4. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011;25(7):1281-1289.
5. Maroso M, et al. Toll-like receptor 4 and highmobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010;16(4):413-419.
6. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol. 2005;78(1):1-8.
7. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191-195.
8. Lamkanfi M, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol. 2010;185(7):4385-4392.
9. Yang H, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012;18:250-259.
10. Schiraldi M, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;209(3):551-563.
11. Weber MD, Frank MG, Tracey KJ, Watkins LR, Maier SF. Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome. J Neurosci. 2015;35(1):316-324.
12. Zurolo E, et al. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain. 2011;134(Pt 4):1015-1032.
13. Venereau E, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209(9):1519-1528.
14. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structurefunctional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013;93(6):865-873.
15. Iori V, et al. Receptor for advanced glycation endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis. 2013;58:102-114.
16. Balosso S, Liu J, Bianchi ME, Vezzani A. Disulfidecontaining high mobility group box-1 promotes N-methyl-D-aspartate receptor function and excitotoxicity by activating Toll-like receptor 4- dependent signaling in hippocampal neurons. Antioxid Redox Signal. 2014;21(12):1726-1740.
17. Tsai MH, et al. Factors predictive of outcome in patients with de novo status epilepticus. QJM. 2009;102(1):57-62.
18. Lévesque M, Avoli M, Bernard C. Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration. J Neurosci Methods. 2016;260:45-52.
19. Lu B, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014;10(6):713-727.
20. Noe FM, et al. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis. 2013;59:183-193.
21. Noè F, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008;131(Pt 6):1506-1515.
22. Antoine DJ, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012;56(5):1070-1079.
23. Antoine DJ, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci. 2009;112(2):521-531.
24. Gardella S, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;3(10):995-1001.
25. Bonaldi T, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551-5560.
26. Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol. 2014;813:109-122.
27. Gorter JA, van Vliet EA, Aronica E. Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav. 2015;49:13-16.
28. Łotowska JM, Sobaniec-Łotowska ME, Sendrowski K, Sobaniec W, Artemowicz B. Ultrastructure of the blood-brain barrier of the gyrus hippocampal cortex in an experimental model of febrile seizures and with the use of a new generation antiepileptic drug-topiramate. Folia Neuropathol. 2008;46(1):57-68.
29. Parfenova H, Tcheranova D, Basuroy S, Fedinec AL, Liu J, Leffler CW. Functional role of astrocyte glutamate receptors and carbon monoxide in cerebral vasodilation response to glutamate. Am J Physiol Heart Circ Physiol. 2012;302(11):H2257-H2266.
30. Gaillard RC. Interaction between the hypothalamopituitary- adrenal axis and the immunological system. Ann Endocrinol (Paris). 2001;62(2):155-163.
31. Tse K, Puttachary S, Beamer E, Sills GJ, Thippeswamy T. Advantages of repeated low dose against single high dose of kainate in C57BL/6J mouse model of status epilepticus: behavioral and electroencephalographic studies. PLoS One. 2014;9(5):e96622.
32. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.
33. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139-162.
34. Williams K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action. Curr Drug Targets. 2001;2(3):285-298.
35. Balosso S, et al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain. 2008;131(Pt 12):3256-3265.
36. Marcon J, et al. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol Dis. 2009;34(1):121-132.
37. Roch C, Leroy C, Nehlig A, Namer IJ. Predictive value of cortical injury for the development of temporal lobe epilepsy in 21-day-old rats: an MRI approach using the lithium-pilocarpine model. Epilepsia. 2002;43(10):1129-1136.
38. Pascente R, et al. Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy. Neurobiol Dis. 2016;93:146-155.
39. Dubé C, Boyet S, Marescaux C, Nehlig A. Relationship between neuronal loss and interictal glucose metabolism during the chronic phase of the lithium-pilocarpine model of epilepsy in the immature and adult rat. Exp Neurol. 2001;167(2):227-241.
40. Leroy C, Pierre K, Simpson IA, Pellerin L, Vannucci SJ, Nehlig A. Temporal changes in mRNA expression of the brain nutrient transporters in the lithium-pilocarpine model of epilepsy in the immature and adult rat. Neurobiol Dis. 2011;43(3):588-597.
41. Ge X, et al. High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem. 2014;289(33):22672-22691.
42. Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS. 2014;11(1):26.
43. Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell. 2013;4(3):163-167.
44. De Simoni MG, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000;12(7):2623-2633.
45. Semah F, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology. 1998;51(5):1256-1262.
46. Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res. 2002;8(6):469-472.
47. Okuma Y, Date I, Nishibori M. [Anti-high mobility group box-1 antibody therapy for traumatic brain injury]. Yakugaku Zasshi. 2014;134(6):701-705.
48. Kim LG, Johnson TL, Marson AG, Chadwick DW, MRC MESS Study group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol. 2006;5(4):317-322.
49. Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012;11(4):331-340.
50. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32(3):281-294.
51. Frigerio F, et al. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia. 2012;53(11):1887-1897.
52. Freeman FG, Jarvis MF. The effect of interstimulation interval on the assessment and stability of kindled seizure thresholds. Brain Res Bull. 1981;7(6):629-633.
53. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press; 2005.
54. Pitkänen A, Kharatishvili I, Narkilahti S, Lukasiuk K, Nissinen J. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res. 2005;63(1):27-42.
55. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH. Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur J Neurosci. 2001;13(4):657-669.
56. Cervo L, et al. Inhibition of glycine transporter-1 reduces cue-induced nicotine-seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. Addict Biol. 2013;18(5):800-811.
57. Clark SR, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab. 2008;28(2):387-394.
58. Jasper HH. The ten-twenty electrode system of the international federation. Electroencephalogr Clin Neurophysiol. 1958;10:370-375.
59. [No authors listed]. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22(4):489-501.
60. Sills GJ, et al. Modern monotherapies in newly diagnosed epilepsy: comparative retention and efficacy. Epilepsia. 2009;50(Suppl 11):492-493.
61. Lehner J, Wittwer C, Fersching D, Siegele B, Holdenrieder S, Stoetzer OJ. Methodological and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res. 2012;32(5):2059-2062.